Where does Supernus Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Supernus Pharmaceuticals, Inc. ranks #7,084 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Supernus Pharmaceuticals, Inc. hold?

Supernus Pharmaceuticals, Inc. holds 47 US utility patents granted between 2015 and 2025, spanning 8 technology areas.

What is Supernus Pharmaceuticals, Inc.'s Innovation Score?

Supernus Pharmaceuticals, Inc. has an Innovation Score of 41.6 out of 100 (top 33% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Supernus Pharmaceuticals, Inc. focus on?

Supernus Pharmaceuticals, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 35 patents, ranking #541 of 6,058 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Supernus Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Supernus Pharmaceuticals, Inc.'s recent grant velocity is -56% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Supernus Pharmaceuticals, Inc.'s patents?

Supernus Pharmaceuticals, Inc.'s patents average 16.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Supernus Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Supernus Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 47 granted patents across 8 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Supernus ranks #7,084 of 49,997 tracked US assignees by granted-patent volume, with 47 patents across 8 technology areas.

#7,084
of 49,997 US assignees by volume: Top 33%
by Innovation Score (41.6/100): 16.5
avg claims per patent: -56%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R7084 · US Corporation #7,084 · 47 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 47 grants
UPPER-Q #7,084/49,997
PHOTO-FINISH Sanford-Burnham…
CPC-NARROW A61P · 8 areas
INNOV-PAR 41.6/100
CLAIMS-RICH 16.5 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -56% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Sanford-Burnham Medical Research Institute (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Supernus’s 41.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.4 pts (32%) Velocity 8.3 pts (20%) Breadth 10.0 pts (24%) Claim depth 9.9 pts (24%)

Qualcomm Incorporated · highest

85
Emseal Joint Systems · near

42
Glasstech · near

42
RareCyte · near

42
Riverbed Technology · near

42
Supernus Pharmaceuti… · this assignee

42
3D Lighting… · lowest

7

What this shows Supernus's Innovation Score is 41.6/100 (top 33% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Supernus?

Each dot is one of Supernus’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Supernus’s own 16.5 claims/patent is ABOVE the 11.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Supernus vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Supernus's grants concentrate

Supernus Pharmaceuticals, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 74.5% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (10 grants) versus a trough of 1 in 2020. By volume, Supernus sits between Systech Corporation and TRW Airbag Systems GMBH.

Supernus's three-year grant acceleration

Supernus Pharmaceuticals, Inc. shows 10 grants in 2022–2024 against only 8 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Systech

47
Sanford-burnham M…

47
Sub-zero Group

47
Sulzer Chemtech

47
THE Doshisha

47
Toyo Denso

47
Trinity Industrial

47
TRW Airbag Systems

47
Supernus Pharmace… ◀

47

What this shows Supernus holds 47 patents at rank #7,084, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Supernus

By rank, the assignees closest to #7,084 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Supernus's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Supernus, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Supernus ranks #541 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (42 here).

Glasstech, Inc. 42 RareCyte, Inc. 42 Emseal Joint Systems, Ltd. 42 Riverbed Technology LLC 42

Supernus's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 33% higher than 67% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Supernus Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	5	10.6%
2016	7	14.9%
2017	10	21.3%
2018	6	12.8%
2019	4	8.5%
2020	1	2.1%
2021	3	6.4%
2022	3	6.4%
2023	2	4.3%
2024	5	10.6%
2025partial year	1	2.1%

Which technologies does Supernus Pharmaceuticals, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 35

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 32

C07D - Heterocyclic Compounds 14

C07C - Acyclic OR Carbocyclic Compounds 10

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 5

Y02A - Technologies FOR Adaptation TO Climate Change 5

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

B01J - Chemical OR Physical Processes, e.g. Catalysis OR Colloid CHEMISTRY; Their Relevant Apparatus 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Supernus Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Supernus Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 74.5% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #7,084 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Supernus Pharmaceuticals, Inc. against Systech Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 41.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.